Company intelligence / Profile preview

Shenzhen Kangtai Biological Products

Shenzhen, Guangdong, Chinabiokangtai.com ↗
Ownership
Private
Employees
~2000
Development stage
Other
01

Overview

Shenzhen Kangtai Biological Products has over a dozen approved or emergency-use human vaccine products. These include the world’s first approved high-dose hepatitis B vaccine and several COVID‑19 vaccines. The company’s COVID‑19 inactivated vaccine was approved for emergency use in China in May 2021. Its adenovirus-vectored COVID‑19 vaccine received approval as a booster dose in Indonesia. The company also holds exclusive rights to manufacture the Oxford–AstraZeneca COVID‑19 vaccine for mainland China

Therapeutic areas
Infectious Diseases
Modalities
Live attenuated viral vaccinesinactivated viral vaccinesrecombinant protein vaccinesbacterial polysaccharide vaccinesbacterial polysaccharide conjugate vaccinescombination vaccinesviral vector vaccinesmRNA vaccines
Industry
Biotech
02

Drug pipeline

14 assets

quadrivalent split-virion influenza vaccine

4

13 more assets in the full pipeline.

03

Partnerships

AstraZeneca – exclusive manufacturing of Oxford–AstraZeneca COVID–19 vaccine for mainland ChinaImmorna Hangzhou Biotechnology – collaboration on mRNA platform development via subsidiary Minhai BiotechnologyPhil. Pharmawealth Inc. – licensing agreement via Beijing Minhai

Beyond the preview

Go deeper on Shenzhen Kangtai Biological Products.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

  • Partners
  • Deal terms
  • Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

  • Funding rounds
  • Investors
  • Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

  • Peer companies
  • Targets
  • Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

  • Platforms
  • Patents
  • Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

  • Company news
  • Sources
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Shenzhen Kangtai Biological Products.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call